Neuromuscular blocking agents: Difference between revisions

Line 25: Line 25:
|[[Atracurium]] (Tracrium)
|[[Atracurium]] (Tracrium)
|90
|90
|30 min or less<ref name=Rang151/>
|30 min or less
|
|
*[[hypotension]], transiently,<ref name=Rang151/> by release of histamine
*Transient [[hypotension]]
*Toxic metabolite called [[laudanosine]], greater accumulation in individuals with renal failure
*Toxic metabolite (laudanosine), greater accumulation in individuals with renal failure
|-
|-
|[[Vecuronium]] (Norcuron)
|[[Vecuronium]] (Norcuron)
Line 39: Line 39:
|45–70
|45–70
|may promote muscarinic block
|may promote muscarinic block
|
|-
|-
|[[Pancuronium]] (Pavulon)
|[[Pancuronium]] (Pavulon)

Revision as of 03:34, 24 February 2015

Background

  • Non-depolarizing
    • Competitively block binding of ACh to its receptors
  • Depolarizing
    • Depolarizing skeletal muscle fiber
    • Persistent depolarization makes the muscle fiber resistant to further stimulation by ACh

Types

Neuromuscular Blocking Agents
Agent Time to onset (seconds) Duration (minutes) Side effects
Non-Depolarizing
Succinylcholine fasciculations, post-operative pain
Depolarizing
Atracurium (Tracrium) 90 30 min or less
  • Transient hypotension
  • Toxic metabolite (laudanosine), greater accumulation in individuals with renal failure
Vecuronium (Norcuron) 60 30–40 Few, may cause prolonged paralysis and promote muscarinic block
Rocuronium (Zemuron) 75 45–70 may promote muscarinic block
Pancuronium (Pavulon) 90 180 or more

Sources